Dr. Phil Bonomi, from Rush University, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
[powerpress]
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
[powerpress]
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.
[powerpress]
Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.
[powerpress]
Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.
[powerpress]
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
[powerpress]
Drs. Nate Pennell, Mary Pinder, and Jack West discuss an encouraging study of dabrafenib, a BRAF inhibitor, for the limited number of NSCLC patients with a BRAF V600E mutation.
[powerpress]
Dr. Mary Pinder of Moffitt Cancer Center reviews the CUSTOM trial, in which the study of molecular markers was expanded to patients with small cell lung cancer and thymic carcinomas.
[powerpress]
Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other lung cancer subtypes.
[powerpress]
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nintedanib (BIBF-1120), an anti-angiogenic multikinase inhibitor, in advanced NSCLC.
[powerpress]
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.